Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 31;109(3):djw255.
doi: 10.1093/jnci/djw255. Print 2017 Mar.

Recommendations for Clinical Trial Development in Follicular Lymphoma

Kami Maddocks  1 , Paul M Barr  1 , Bruce D Cheson  1 , Richard F Little  1 , Lawrence Baizer  1 , Brad S Kahl  1 , John P Leonard  1 , Nathan Fowler  1 , Leo I Gordon  1 , Brian K Link  1 , Jonathan W Friedberg  1 , Stephen M Ansell  1
Affiliations
Review

Recommendations for Clinical Trial Development in Follicular Lymphoma

Kami Maddocks et al. J Natl Cancer Inst. .

Abstract

Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies. There is an urgent need to integrate novel therapeutic agents into the treatment regimens for these patients to improve outcomes with continued evaluation of biomarkers indicative of prognosis and effects of these regimens on quality of life.

PubMed Disclaimer

References

    1. Anderson JR, Armitage JO, Weisenburger DD.. Epidemiology of the non-Hodgkin’s lymphomas: Distributions of the major subtypes differ by geographic location. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998;1827:717–720. - PubMed
    1. Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the University of Iowa/Mayo Clinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol. 2013;3126:3272–3278. - PMC - PubMed
    1. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;1045:1258–1265. - PubMed
    1. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international lymphoma prognostic factor project. J Clin Oncol. 2009;2727:4555–4562. - PubMed
    1. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d-Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998;167:2332–2338. - PubMed

Substances